Veradermics, Incorporated (MANE)
| Market Cap | 4.37B |
| Revenue (ttm) | n/a |
| Net Income | -83.37M |
| EPS | -111.91 |
| Shares Out | 41.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 496,309 |
| Open | 107.88 |
| Previous Close | 107.85 |
| Day's Range | 105.23 - 110.79 |
| 52-Week Range | 32.00 - 117.71 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 83.33 (-21.49%) |
| Earnings Date | Mar 30, 2026 |
About MANE
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MANE stock is "Strong Buy." The 12-month stock price target is $83.33, which is a decrease of -21.49% from the latest price.
News
Veradermics 3.84M share Secondary priced at $100.00
The deal size was increased to 3.84M shares from 3.35M and priced below last closing price of $106.55. Jefferies, Leerink, Citi and Cantor Fitzgerald are acting as joint book running
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Veradermics announces offering of 3.35M shares of common stock
Veradermics (MANE) announced that it has launched a proposed public offering of 3.35M shares of common stock pursuant to a registration statement filed on Form S-1 with the SEC. All
Veradermics Announces Launch of Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Veradermics files to sell 3.35M shares of common stock
17:19 EDT Veradermics (MANE) files to sell 3.35M shares of common stock
Veradermics price target raised to $120 from $85 at Citi
Citi raised the firm’s price target on Veradermics (MANE) to $120 from $85 and keeps a Buy rating on the shares after the company announced positive topline results from Part
Veradermics Transcript: Study result
Top-line results from a large phase II/III trial show VDPHL01 achieved significant hair growth and high patient satisfaction with a strong safety profile. Both once- and twice-daily regimens outperformed existing therapies, and market research indicates high intent to prescribe and use if approved.
Veradermics announces VDPHL01 met all primary, secondary endpoints
Veradermics (MANE) announced positive topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating VDPHL01, a proprietary extended-release oral m...
Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302' Clinical Trial in Male Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302' Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics reports Q4 net loss $21.8M vs $5.7M last year
Cash, cash equivalents, and marketable securities totaled $141.9 million as of December 31, 2025. “2025 was a landmark year for Veradermics (MANE), marked by significant progress in advancing Phase 3
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
Veradermics management to meet with Jefferies
Dinner Meeting to be held in New York on March 24 at 6 pm hosted by Jefferies.
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
Veradermics Transcript: Leerink Global Healthcare Conference 2026
A novel extended-release oral minoxidil tablet is advancing through phase III trials, showing rapid and robust hair growth with improved safety and convenience. The product targets a large, motivated market, leverages a strong IP portfolio, and is positioned for broad adoption through dermatology, primary care, and telehealth channels.
Veradermics to Participate in Upcoming March Investor Conferences
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
Veradermics initiated with an Overweight at Cantor Fitzgerald
As previously reported, Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Veradermics (MANE) with an Overweight rating and no price target Veradermics is a late clinical-stage biotech fo...
Veradermics initiated with an Outperform at Leerink
Leerink initiated coverage of Veradermics (MANE) with an Outperform rating and $75 price target The firm notes hair loss is a significant market, impacting about 50M men and about 30M
Veradermics initiated with a Buy at Citi
Citi initiated coverage of Veradermics (MANE) with a Buy rating and $85 price target The firm believes the company’s VDPHL01 is positioned to become the first FDA-approved oral minoxidil for
Veradermics initiated with a Buy at Jefferies
Jefferies initiated coverage of Veradermics (MANE) with a Buy rating and $75 price target The firm thinks the company’s Phase 3 study has a high likelihood of success. The company’s
Veradermics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Veradermics (MANE) with an Overweight rating.
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the N...
Veradermics completes enrollment in Phase 3 trial of VDPHL01
Veradermics (MANE) announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previousl...
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...